Breaking News
1 hour ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pfizer moves its 25-valent pneumococcal conjugate vaccine into Phase 3 pediatric trials following positive Phase 2 immunogenicity data across all serotypes.
Pharma Now Editorial Team

Immix Biopharma reports 95% CR rate in NEXICART-2, with BLA submission targeted following March 2027 one-year follow-up data readout.
Pharma Now Editorial Team
Cognition Therapeutics met with FDA on May 20 to align on a registrational program for zervimesine in DLB psychosis; formal minutes expected June 2026.
Pharma Now Editorial Team

Novartis presents Phase 1 actinium-225 RLT and Pluvicto data at ASCO 2026, raising new manufacturing complexity for radiopharmaceutical facilities.
Pharma Now Editorial Team
